Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Waters

Showing results (41-50 of 134) with videos related to

Pageof 14
Sort By:
Antiviral Therapy|September 9, 2011
The value of screening HIV-infected individuals for didanosine-related liver disease?Andrew Scourfield, Akil Jackson, Laura Waters, et al.
Journal of the International AIDS Society|November 15, 2014
The potential impact of new national guidance on primary prevention of cardiovascular disease in people living with HIVNadia Ahmed, Sarah Bradley, Patrick Pearson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 28, 2022
Broadly Neutralizing Antibodies for Human Immunodeficiency Virus Treatment: Broad in Theory, Narrow in RealityLaura Waters, Rosa de Miguel-Buckley, Sébastien Poulin, et al.
AIDS (London, England)|January 18, 2011
A comparison of patients' attitudes to antiretroviral toxicities between the UK and UgandaMark Nelson, Strachan Mackenzie, Stuart Yau, et al.
Science & Justice : Journal of the Forensic Science Society|April 25, 2018
The use of a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding of newly emerging benzodiazepinesLaura Waters, Kieran R Manchester, Peter D Maskell, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2008
The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimenLaura Waters, Sundhiya Mandalia, Paul Randell, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 19, 2005
Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS-defining eventsJustin Stebbing, Laura Waters, Sundhiya Mandalia, et al.
Drug Testing and Analysis|May 5, 2017
The emergence of new psychoactive substance (NPS) benzodiazepines: A reviewKieran R Manchester, Emma C Lomas, Laura Waters, et al.
HIV Medicine|October 11, 2021
No overall impact on rate of weight gain with integrase inhibitor-containing regimens in antiretroviral-naïve adultsJames E Burns, Oliver Stirrup, Laura Waters, et al.
AIDS (London, England)|March 24, 2012
Discontinuation of Atripla as first-line therapy in HIV-1 infected individualsAndrew Scourfield, Jiexin Zheng, Suchitra Chinthapalli, et al.
Pageof 14

Showing results (41-50 of 134) with videos related to

Sort By:
Pageof 14
Antiviral Therapy|September 9, 2011
The value of screening HIV-infected individuals for didanosine-related liver disease?Andrew Scourfield, Akil Jackson, Laura Waters, et al.
Journal of the International AIDS Society|November 15, 2014
The potential impact of new national guidance on primary prevention of cardiovascular disease in people living with HIVNadia Ahmed, Sarah Bradley, Patrick Pearson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 28, 2022
Broadly Neutralizing Antibodies for Human Immunodeficiency Virus Treatment: Broad in Theory, Narrow in RealityLaura Waters, Rosa de Miguel-Buckley, Sébastien Poulin, et al.
AIDS (London, England)|January 18, 2011
A comparison of patients' attitudes to antiretroviral toxicities between the UK and UgandaMark Nelson, Strachan Mackenzie, Stuart Yau, et al.
Science & Justice : Journal of the Forensic Science Society|April 25, 2018
The use of a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding of newly emerging benzodiazepinesLaura Waters, Kieran R Manchester, Peter D Maskell, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2008
The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimenLaura Waters, Sundhiya Mandalia, Paul Randell, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 19, 2005
Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS-defining eventsJustin Stebbing, Laura Waters, Sundhiya Mandalia, et al.
Drug Testing and Analysis|May 5, 2017
The emergence of new psychoactive substance (NPS) benzodiazepines: A reviewKieran R Manchester, Emma C Lomas, Laura Waters, et al.
HIV Medicine|October 11, 2021
No overall impact on rate of weight gain with integrase inhibitor-containing regimens in antiretroviral-naïve adultsJames E Burns, Oliver Stirrup, Laura Waters, et al.
AIDS (London, England)|March 24, 2012
Discontinuation of Atripla as first-line therapy in HIV-1 infected individualsAndrew Scourfield, Jiexin Zheng, Suchitra Chinthapalli, et al.
Pageof 14